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The interleukin-I (IL-l) receptor on rat bone marrow cells was investigated using ‘251-labeled IL-la and -1s. These radiolabeled ligands bound 
to the rat bone marrow cells in a specific and saturable manner with Kd values of 0.36 f 0.072 nM and 1.9 + 0.27 nM, respectively. In a competitive 
binding experiment, IL-la and -1fi inhibited the binding of lzsI-IL-la with K, values of 0.35+0.041 nM and 2.9&- 1.0 nM. The binding of 12sI-IL-l~ 
was inhibited by IL- la and -l/I with K, values of 0.27 k 0.020 nM and 0.74 k 0.12 nM. In cross-linking experiments, iZSI-IL-la was covalently incor- 
porated into two proteins of 163 kDa and 63 kDa. These results suggested the presence of two binding proteins for IL-l on the rat bone marrow 
cells. 
Interleukin-1 receptor; Interleukin-la; Interleukin-l/I (Rat bone marrow cell, Mouse BALB/3T3 cell) 
1. INTRODUCTION 
IL-la and IL-l/3 are two distinct cytokines function- 
ing as the regulators of inflammatory reactions or im- 
mune responses [l]. The distribution of the IL-l 
receptor on fibroblasts, T cells and B cells is consistent 
with the known biological effects of IL-l on these cells 
[2,3]. In spite of low homology (26%) of amino acid se- 
quence between human IL-la and IL-lb [4], both bind 
to the same cell-surface receptor on T cells [5,6]. 
Molecular weight of the IL-l receptor has been 
reported for various types of cell; 80 kDa for EL-4 cells 
[7], LBRM-33-IA5 cells [2] and BALB/3T3 cells [8], 
68 kDa for Raji cells [7] and 60 kDa for human Epstein 
Barr virus-transformed B lymphocytes [9]. The IL-l 
receptor of 80 kDa was purified to homogeneity from 
EL-4 cells [lo], and the cDNA clone was isolated by 
Dower et al. [ll]. 
In recent years, many investigators have been in- 
terested in the regulation of hematopoiesis by IL-l. The 
addition of IL-l induces the in vitro production of 
granulocyte/macrophage colony-stimulating factor 
(CSF) and granulocyte CSF by mouse bone marrow 
stromal cells [ 121, fibroblasts [13], endothelial cells 
[ 14- 161 and mononuclear phagocytes [ 171 of human 
origin. IL-l enhances the ability of several kinds of 
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CSF to stimulate colony formation by primitive 
hematopoietic progenitors in vitro [ 18-201. However, 
the IL-l receptor on primitive hematopoietic pro- 
genitor cells has not yet been identified. In this paper, 
we will report the first demonstration of IL-l binding 
protein in rat bone marrow cells by the use of 12’1- 
labeled human recombinant IL-l@ and IL-lo. 
2. MATERIALS AND METHODS 
2.1. Materials 
Recombinant human IL-la and IL-l,0 were expressed in E. coli and 
purified to homogeneity as previously described [21]. BALB/3T3 
fibroblast (the American Type Culture Collection) maintained in a 
Dulbecco’s minimum essential medium (MEM) containing 10% fetal 
calf serum (FCS). Bone marrow cells were obtained by flushing the 
femora of Sprague-Dawley rats (6-10 weeks) with an (r-MEM con- 
taining 10% FCS followed by incubation for 2 h in a COz-incubator. 
The non-adherent cells were collected and used for the IL-l binding 
assay. 
2.2. IL-l receptor assay 
Recombinant human IL-la was labeled with “‘1 by utilizing Iodo- 
gen reagent (Pierce Chemical Co.) [22]. The radioactive IL-la was 
purified by gel filtration. The specific activity was 130-150 &i//g. 
Rat bone marrow cells (5 x 106) were incubated with the ‘z51-IL-l in 
the presence of various concentrations of unlabeled IL-l in 200 pl of 
wMEM containing 10% FCS. The incubation was terminated by cen- 
trifugation layering on 200~1 of a phthalate oil mixture in 
polyethylene centrifuge tubes as described [2]. Non-specific binding 
was determined in the presence of 1 fig/ml unlabeled IL-la. The 
biologic activity of the radiolabeled IL-l as assayed by its growth in- 
hibitory activity against human melanoma A375 cell [21] was the 
same as that of unlabeled IL-l. For the IL-l receptor assay in situ 
BALB/3T3 cells were incubated with 500 ,ul of Dulbecco’s MEM con- 
taining 10% FCS in a 12-well plate (Corning) for 2 h at 4°C. The cell 
monolayers were then rinsed with 3 changes of PBS (1 ml), and 
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solubilized with 1 ml of a mixture of 1% SDS and 0.2 N NaOH. The 
radioactivity was counted in a gamma counter. 
2.3. Chemical cross-linking of ceils and SDS-polyacrylamide 
gel electrophoresis 
Bone marrow cells (5 x 10’) were incubated for 4 h with “‘I-IL-la 
at 4°C in the presence or absence of 1 rg/ml IL-la. BALB/3T3 cells 
(5 x 10’) were incubated for 2 h under the same conditions. The in- 
cubation mixture was centrifuged, and the pellet was washed 3 times 
with PBS. The cells were cross-linked with ‘251-IL-l~ by disuc- 
cinimidyl suberate (Pierce Chemical Co.) (1 mg/ml) at room 
temperature for 1 h. The labeled and cross-linked cells were extracted 
with PBS containing 1070 Triton X-100 and a mixture of protease in- 
hibitors [lo] on ice for 15 min. The mixture was centrifuged at 10000 
x g for 30 min at 4°C. The supernatant was mixed with an equal 
volume of the 1% SDS and 5% 2-mercaptoethanol. The mixture was 
boiled for 3 min and then subjected to 7.5% SDS-polyacrylamide gel 
electrophoresis according to the method of Laemmli [23]. The gels 
were fixed, dried, and exposed to a Kodak XAR-5 film for 3-7 days 
at -70°C. 
3. RESULTS AND DISCUSSION 
Rat bone marrow cells were incubated with lz51- 
labeled recombinant human IL-la or IL-lb 
(600 Ci/mmol, Amersham). The specific binding of 
‘251-IL-la reached an equilibrium after 4 h incubation 
at 4°C. As shown in fig.la, the binding of 12’I-IL-lcu to 
the rat bone marrow cells at 4°C was saturable, and the 
non-specific binding of the radiolabeled ligand in the 
presence of 1 pg/ml unlabeled IL-la, was 1%50% of 
the total binding. Scatchard analysis of the data of 
fig.la showed the presence of a single class of IL-la 
binding site (241 sites/cell) with a & of 0.31 nM 
(fig.lb). On the other hand, ‘251-IL-lfl also bound to 
the rat bone marrow cells (fig.lc). Scatchard analysis 
Fig.1 
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Data from (a) and (c) were replotted in the Scatchard 
coordinate system (b and d). 
Table 1 
Properties of IL-1 receptor on rat bone marrow cells 
A Kd 0.36 f 0.07 nM (n = 3) 1.9 k 0.27 nM (n = 3) 
sites/cell 190 5 32 350 * 110 
B Ki IL-la 0.35 + 0.041 nM (n = 4) 0.27 k 0.02 nM (n = 3) 
IL-l,6 2.9 + 1.0 nM (n = 4) 0.74 & 0.12 nM (n = 3) 
(A) Parameter values were obtained by analysing the equilibrium 
binding data in fig.1 and 2 other experiments. (B) Ki values were 
obtained from the data of fig.2 (A and a) and 2 or 3 other 
experiments 
showed that the rat bone marrow cells had a single class 
of IL-14 binding site (577 sites/cell) with a & of 
1.4 nM (fig.ld). Results averaged from three similar 
experiments are listed in table 1. 
As shown in fig.2A and a, the rat bone marrow cells 
were incubated with various concentrations of unlabel- 
ed IL-la and IL-lfl for the displacement of a known 
amount of 1251-IL-la or IL-l@ which was bound to the 
rat bone marrow cells. The experimental results in- 
dicated that the IL-la, and IL-1B molecules bound to a 
common class of receptor site. However, the Ki values 
for ‘251-IL-la were different by almost one order of 
magnitude between IL-la (0.340 nM) and IL-lfl 
(5.7 nM). The Ki values for 1251-IL-l,B were 0.29 nM 
with IL-la and 0.69 nM with IL-l@, The average Ki 
values are summarized in table 1. Thus, the affinity of 
the receptor on the rat bone marrow cells for IL-la was 
several times higher than that for IL-lfl. The difference 
10'11 1(-J-10 10'9 10-11 @O 10-9 
Unlabeled ILJ (MI 
Fig.2. Cross-competition between IL-la (0) and IL-lfi (0) on rat 
bone marrow cells and BALB/3T3 cells. Rat bone marrow cells (A, 
5 x lo6 cells: a, 7.6 x IO6 cells) were incubated with 140 pM “‘I- 
IL-la (A) and 714 pM ‘251-IL-1fl (a). BALB/3T3 fibroblasts (1 x lo6 
cells) were incubated with 70 pM ‘251-IL-la (B) and 397 pM ‘251- 
IL-l@ (b). Maximal binding was measured in the presence of the ‘251- 
ligands alone. (A) ‘251-IL-lcu 1354 cpm; (a) ‘251-IL-1B 1817 cpm; (B) 
L251-IL-lcu 3412 cpm; (b) ‘251-IL-lfl 3770 cpm. 
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Fig.3. SDS-polyacrylamide gel electrophoresis of IL-l receptors of 
rat bone marrow cells (lanes 1 and 2) and BALB/3T3 fibroblasts 
(lanes 3 and 4) covalently cross-linked with ‘zsI-IL-l~. Lanes 2 and 
4 contained 1 pg/ml unlabeled IL-la. Lanes Mr are for the molecular 
mass markers. Positions of 180 kDa and 80 kDa are indicated with 
arrows. 
in the Ki values between IL-la and IL-b3 is consistent 
with the difference in the hemopoietin 1 activity bet- 
ween IL-10 and IL-lfl [ 191. The same experiments with 
IL-la and IL-l,& were carried out using mouse 
BALB/3T3 fibroblasts as presented for fig.ZB and b. 
In the case of BALB/3T3 cells, both IL-la and IL-l/3 
molecules bound to a common class of receptor site 
with an approximately equal affinity. The Ki value for 
‘251-IL-1~ was 109 pM (IL-la and IL-lp), and those 
for 1251-IL-lfl were 103 pM (IL-la) and 143 pM 
(IL-l,@. Similar results have been reported in several re- 
cent works with pig synovial fibroblasts and articular 
chondrocytes [5], and human dermal fibroblasts [6]. 
When 12’I-IL-la, was incubated with the rat bone 
marrow cells in the presence of a homobifunctional 
cross-linker, two major proteins of molecular weights 
180 kDa and 80 kDa were radiolabeled upon SDS- 
polyacrylamide gel electrophoresis (fig.3). Subtracting 
17 kDa (molecular mass of IL-l), the molecular mass 
values of the cross-linked proteins were estimated to be 
163 kDa and 63 kDa. The binding of these two proteins 
with r2’I-IL-la was reduced in parallel depending on 
the concentration of unlabeled IL-la (fig.4a). The 
same results were obtained with unlabeled IL-lfl 
(fig.4b). Thus, the two proteins could bind to IL-la or 
IL-lp with an approximately equal affinity. In the same 
experiment, the IL-l receptor of BALB/3T3 cells show- 
ed a molecular weight of approximately 80 kDa 
(97 kDa as a conjugate with IL-1~). 
The molecular weight of the IL-l receptor was also 
reported to be 80 kDa for EL-4 cells [7], 
LBRM-33-lA5 cells [2], human normal and embryonic 
lung fibroblasts [24]. In contrast, the IL-l receptors of 
Raji cells [7] and Epstein Barr virus-transformed B 
lymphocytes [9] showed a molecular mass of 68 kDa 
and 60 kDa, respectively. Horuk et al. [7] suggested 
that such a heterogeneity in molecular weight reflects a 
structural difference of the receptor proteins. The two 
main cross-linked proteins with molecular masses of 
180 kDa and 80 kDa on rat bone marrow cells may be 
subunits composing a receptor complex. But, it should 
be noted that the rat bone marrow cells used in this 
work are not a homogeneous cell population. It is 
possible that the two radiolabeled proteins are at- 
tributable to two different types of cell. 
Almost the same results were obtained with mouse 
bone marrow cells (data not shown). The IL-l receptor 
reported in this paper may be a common IL-l receptor 
for bone marrow cells of various animals. Namely, two 
binding proteins of different sizes were found. The af- 
finity for the receptor was different between IL-la and 
IL-l/Y. Further characterization of the structure and 
function of IL-l receptor on bone marrow cells requires 
the cloning of the receptor cDNA as recently reported 
for the IL-l receptor cDNA from EL-4 cells [ll]. 
Very recently, Parker et al. suggested the presence of 
IL-l receptor on granulocytes and granulocytic pro- 
genitors from bone marrow cells of untreated mice 
[25]. Identity of their IL-l receptor with our binding 
proteins of rat bone marrow cells awaits further in- 
vestigations. 
Fig.4. Inhibition of ‘251-IL-lcu binding to two binding proteins by unlabeled IL-la or IL-&Y. (A) Rat bone marrow cells were covalently 
radiolabeled with ‘251-IL-lcu in the presence of unlabeled IL-la (lanes 1-5: 0, 1, 10, 100 and 1000 ng/ml). (B) Experimental conditions were the 
same as shown in (A) except that IL-lfl was used instead of IL-la. Positions of 180 kDa and 80 kDa are indicated with arrows. 
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